Peter L. Salgo, MD: With all of this, what do you see as the future of treating anemia and CKD [chronic kidney disease] going forward? Robert Provenzano, MD, FACP, FASN: Well. Peter L. Salgo, MD: It ...

Additional population-based studies of autoimmune hemolytic anemia and its management are needed to reduce mortality in this patient population. Autoimmune hemolytic anemia (AIHA) is typically a ...

Please provide your email address to receive an email when new articles are posted on . The executive summary of recommendations and practice statements included clinical assessment steps, evaluation ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

A new guideline from the Kidney Disease: Improving Global Outcomes (KDIGO) group provides updated recommendations on the management of anemia in chronic kidney disease (CKD), reflecting substantial ...

Anemia in myelofibrosis significantly affects survival and quality of life, with severe anemia reducing median survival fourfold compared to non-anemic patients. Transfusion dependency in ...

While mild anemia is generally treatable, some severe forms, like thalassemia and aplastic anemia, can lead to life-threatening complications if untreated due to the body’s organs not receiving enough ...

Autoimmune haemolytic anaemia (AIHA) comprises a group of disorders in which autoantibodies target erythrocytes, leading to premature red-cell destruction. The condition is broadly classified into ...

As use of GLP-1 receptor agonists (RAs) continues to rise exponentially, awareness of its most common side effects, such as nausea and vomiting, is growing. But the drugs come with some lesser-known ...

The American Society of Hematology (ASH) released guidelines on the diagnosis and management of severe acquired aplastic anemia, a rare and life-threatening bone marrow failure disorder. The ...